"I love DNA Damage Response | DDR Company | Artios Pharma"

2022-05-16 18:24:29

HomeAboutLeadershipScientific AdvisorsBoardScienceTargeting the DDRClinical TrialsPipelineInvestors & PartnersOur InvestorsOur PartnersMerck KGaANovartisCareersOur OpportunitiesOur TestimonialsOur BenefitsCore ValuesNews & EventsPress releaseMedia coverageConferencesContact Us Defining next generation DNA Damage Response Medicines We are developing breakthrough cancer treatments that target DNA Damage Response (DDR) pathways to specifically destroy certain devastating cancers that are difficult to treat. Artios' ATR Inhibitor, ART0380, Progressing Into Phase 1b Evaluation Unparalleled Experience in DDRWe are Artios. We believe DDR-targeting therapies can play a significant role in the treatment of malignant disease, and we aim to take advantage of the full range of DDR therapeutic strategies to unlock new opportunities for patients.Our team is recognized as innovators in DDR drug discovery, with experience that dates back to its inception. Our scientific founders, Niall Martin, PhD, and Graeme Smith, PhD, invented a blockbuster PARP inhibitor (now marketed as Lynparza® (olaparib) by AstraZeneca) and pioneered successful DDR programs while at KuDOS. Our industry-leading expertise in this space has yielded a robust pipeline and platform with immense potential which has led to collaborations with major pharma partners.Get to know us Our PlatformOur comprehensive approach exploits the full range of DDR-based therapeutic opportunities.Our capabilities allow us to move beyond a single approach, such as synthetic lethality, to develop drugs with a broad range of applications. Our approach includes developing inhibitors with monotherapy potential, overcoming acquired or de novo resistance to existing DDR-targeted therapies, including PARP inhibitors, supercharging existing DNA-targeting treatments through combinations, and expanding the reach of the immune response.See how Our Pipeline ART0380 - ATR inhibitor ART4215 - Polθ inhibitor RLT Sensitizers - Novartis Nucleases – Merck KGaA Drug Discovery Platform ART0380 - ATR inhibitor Our orally dosed ataxia telangiectasia and Rad3-related protein (ATR) inhibitor, ART0380, has the potential to induce DNA damage in sensitive cancer tissue while preserving DNA integrity in healthy tissue. ART0380 is being developed as an oral anticancer agent as both a monotherapy and in combination with established as well as novel agents that cause DNA damage or suppress a cancer cell’s ability to repair DNA damage. Learn more ART4215 - Polθ inhibitor Our inhibitor offers the unprecedented potential to harness the power of the DDR inhibition to specifically target tumor cells while sparing normal tissue from toxicity. It may allow for effective and widespread use across multiple tumor types including PARP inhibitor resistant cancers, as a combination treatment with other DDR inhibitors, or in combination with DNA damaging agents. Learn more RLT Sensitizers - Novartis In March 2021, Artios entered into a research collaboration and license agreement with Novartis; a global healthcare company based in Switzerland (https://www.novartis.co.uk/ ) to identify DNA Damage Response (DDR) targets and the agents capable of modulating these targets, for use with Novartis’s proprietary radioligand therapies or as a monotherapy. Learn more Nucleases – Merck KGaA In December 2020, Artios entered into a research collaboration and license agreement with Merck KGaA , Pharmaceutical company in Darmstadt, Germany, a leading team of specialists in Healthcare and Life Sciences (https://www.merckgroup.com/en/company.html) for the identification of novel DDR nuclease inhibitors in the oncology field. Learn more Drug Discovery Platform Alternative Lengthening of Telomeres (ALT)The development of our DDR platform has given us the ability to identify novel DDR targets in relevant disease setting where there is unmet medical need.Learn moreImmuno- oncology CombinationsMedicines that enable the immune system to target and kill cancer cells (immunotherapy) are therapeutics that have proven to be a highly effective means of treating a select group of cancers. Learn more Targeting DDR Taking control of the DNA Damage Response × In the news Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation Artios attending the AACR in New Orleans 8-12 April 2022 Graeme Smith, CSO and Helen Robinson, VP Biology attending the 5th Digital DDR, ATR, & PARP Summit – 25/26 January 2022 Advancement Through PartnershipWe believe DDR-based therapies have more opportunity than we can explore alone, and we look to leverage our expertise and maximize the long-term value of our discoveries with strategic partnerships.Partner with us Quick Links HomepageAboutScienceOur InvestorsOur PartnersNews & EventsCareersContact Us ContactUK Office: +44 (0)1223 867 900General enquiries: [email protected]: [email protected]: [email protected] Our career opportunities Our careers © Artios Pharma 2022 | Website by Granite 5 Follow on twitter Follow on LinkedIn Terms & conditions | Privacy policy | Site map #g5-gdpr-cookie-bar{background-color: #e8e8e8;color: #000;font-size: 18px;}#g5-gdpr-cookie-accept svg {fill: #000;}We use cookies to collect data, please see our privacy policy.